A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the
long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and
mixed hyperlipidemia.